2024 ACA Nashville Program Book_154th Congress of Correction

York Department of Correctional Services/ Hudson Correctional Facility, Hudson, New York Speakers: Colleen Cannataro , Director of Surgical Coordination, New You Plastic Surgery, Roslyn, New York; Jeremy Nikfarjam , M.D., CEO, Medical Director, New You Plastic Surgery, Roslyn, New York Implementing Medications for Opioid Use Disorder (MOUD) in Correctional Settings: Relevant Federal Regulations and Requirements for Optimizing Care Room 202B Primary Area of Focus: Healthcare/Wellness Primary Community of Focus: Adult Corrections The opioid epidemic has disproportionately affected individuals involved in the criminal justice system, with a high prevalence of opioid use disorder (OUD) among incarcerated populations. Providing evidence-based treatment, particularly medications for opioid use disorder (MOUD), is crucial for improving health outcomes, reducing recidivism, and promoting successful reentry. However, implementing MOUD in correctional settings presents unique challenges. This presentation, led by leadership from the Substance Abuse and Mental Health Services Administration (SAMHSA) and the Drug Enforcement Administration (DEA), will explore the revised 42 CFR Part 8 rule and its implications for expanding access to MOUD in carceral settings. The presentation will discuss the importance of providing MOUD, and provide an overview of medication options, including methadone, buprenorphine, and extended-release naltrexone. The presentation will review relevant regulations and requirements associated with providing MOUD in correctional settings, including collaborating with opioid treatment programs (OTPs), leveraging mobile OTPs, and using the DEA hospital/clinic registration. Attendees will gain valuable insights into navigating the federal regulations associated with implementing MOUD in carceral settings. Learning Objectives:

• At the conclusion of this session, participants will be able to understand the revised 42 CFR Part 8 rule and its implications for expanding access to MOUD in correctional settings. • At the conclusion of this session, participants will be able to recognize the importance of providing MOUD in carceral settings. • At the conclusion of this session, participants will be able to identify the medication options available for treating OUD in correctional settings, including relevant regulations and requirements. the models for integrating MOUD into correctional settings, including collaborating with OTPs, leveraging mobile OTPs, and using DEA registration. Moderator: Meg Chapman , M.A., Policy Advisor, Bureau of Justice Assistance, U.S. Department of Justice, Washington, D.C. Speakers: Yngvild Olsen , M.D., MPH, Director, Center for Substance Abuse Treatment, SAMSHA, Rockville, Maryland; Coralie Terpening , Staff Coordinator, Drug Enforcement Administrator, Washington, D.C. • At the conclusion of this session, participants will be able to identify

WORKSHOPS Sunday, Aug. 18 ▼ 10–11:30 a.m.

140 — ACA 154 th Congress of Correction | Nashville